Clare Brown Partner

Clare specialises in corporate and securities law, with a particular focus on equity capital markets, venture capital and M&A.

She has experience in cross-border and domestic corporate transactions including advising on equity fundraisings, private financing and investment transactions, regulated and private M&A, securities regulatory and ASX compliance issues, ESOPs and other general corporate matters.

She regularly acts for companies and investors in the healthcare, medical device and biotechnology sector, as well as the technology industry more broadly. Clare also regularly represents early and growth stage companies and venture capital firms that invest in them.

Clare also has significant experience advising US clients doing business in Australia and Australian clients doing business in the US, including having acted for a number of US companies listed on ASX.


Capital markets

CurveBeam AI Limited (ASX:CVB)

Advised on its 2023 initial public offering and listing on the ASX.

EBR Systems, Inc (ASX:EBR)

Advised on its 2021 A$110 million IPO and ASX listing and its placement and SPP in 2023.

ImpediMed Limited (ASX:IPD)

Advised on its placement and share purchase plan which raised A$35 million in 2023.

Visioneering Technologies, Inc (ASX:VTI)

Advised on its non-renounceable entitlement offer and director placement in 2023.

Imricor Medical Systems, Inc. (ASX:IMR)

Advised on its pre-IPO financing and IPO and ASX listing in 2019 and follow-on capital raisings in 2020 -2024 (including its recent ANREO).

Laybuy Group Holdings Limited (ASX:LBY)

Advised Laybuy Group Holdings Limited on its $80M IPO and ASX-listing in 2020, and its placement and SPP in 2021.

Blackmores Limited (ASX:BKL)

Advised on its pre-IPO financing and IPO and ASX listing in 2019 and follow-on capital raisings in 2020 -2024 (including its recent ANREO).

Osprey Medical Inc (ASX:OSP)

Advised on its renounceable entitlement offer to raise up to A$15.5 million.

Wilsons Corporate Finance

Advised lead manager on multiple capital raisings in the energy and resources sector.

Venture capital

Cardiac Dimensions

Advised on its Series B, Series C and Series D financings.

OneVentures Healthcare Fund

Advised on its investment in ImmVirX.

Popgun Labs

Advised on its Series A financing in 2021 and 2023.

Seven West Media Investments

Advised on various VC investments.

CEFC / Virescent Ventures Pty Ltd

Advised on its investment in Xefco.

Liverpool Partners

Advised on its convertible note investment in HealthEngine.

Simplify Medical

Advised on convertible note financings in 2019 and 2020.

Orbx Limited

Advised on its pre-IPO funding round and proposed IPO.

Curvebeam AI Limited

Advised on its 2022 pre-IPO funding rounds.

Mergers, acquisitions and restructures

Simplify Medical Pty Ltd

Advised Simplify Medical on its acquisition by NuVasive, Inc. for US$150 million plus additional milestone payments.

StraxCorp/CurveBeam AI Limited

Advised on StraxCorp’s merger with Curvebeam, LLC.

Blackmores Limited

Advised on infant formula joint venture with Bega Cheese.

EnGeneIC Limited

Advised on redomicile to Bermuda via scheme of arrangement.


Protecht Group

Advice on implementation of management equity plan.

Liverpool Partners

Advice on equity incentive plans for various portfolio companies.


Advised on ZEPO plan.

Various ASX-listed companies companies (CurveBeam AI Ltd, LaybuyGroup Holdings Limited, Blackmores Limited, Visioneering Technologies, Inc. and ImpediMed Limited)

Advice on equity incentive plans.

Career & qualifications


  • Bachelor of Laws, University of Wollongong
  • Bachelor of Arts, University of Wollongong


  • Law Society of New South Wales
  • Law Society of South Australia

International experience

  • Acted for a number of United States med-tech companies on their proposed Australian IPOs and ASX-listings



Insights Read more insight

ASX insights: navigating the evolving IPO landscape in 2024

The ASX is likely to introduce a series of new measures in 2024 aimed at streamlining aspects of the IPO listing process, as outlined in a recent adviser briefing.

The death of the employee share option? And a new complexity regarding the on-sale of shares

From 1 October, we expect to see significant changes in the way that companies offer equity to their Australian personnel. For many businesses, new rules in the Corporations Act significantly...

Capital raising relief – a cautionary tale

ASIC and ASX have both announced temporary changes to their respective regulatory regimes to facilitate capital raisings for listed entities in response to the economic impact of COVID-19.